Buchumschlag

Letter: Timely Follow‐Up in Cirrhosis—A Key Public Health Intervention

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Mo‐Yao Tan, Ping Zhang, Ming Gao
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Editorial: Timely Follow‐Up in Cirrhosis: How Does It Work?
von: Nina Kimer, et al.
Veröffentlicht: (2024)

Timely Follow‐Up After a First Diagnosis of Cirrhosis is Associated With Reduced Mortality but No Impact on Rehospitalisations: A Population‐Based Cohort of 8852 Patients
von: Max S. Schechter, et al.
Veröffentlicht: (2024)

Letter: The Unresolved Issue of NSBB Confounding in Statin Research for Cirrhosis
von: Deliang Huang, et al.
Veröffentlicht: (2026)

Letter: Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
von: Zhanbo Qu
Veröffentlicht: (2026)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’
von: Sai Kiran Kuchana, et al.
Veröffentlicht: (2026)

Letter: Amino Acid Imbalance and Mortality in Cirrhosis—Interpretation and Methodological Considerations. Authors' Reply
von: Yuki Utakata, et al.
Veröffentlicht: (2026)

Letter: Pharmacotherapy for Alcohol Dependence in Cirrhosis—By Addressing One Issue Do We Create Another?
von: Andrew W. Nguyen, et al.
Veröffentlicht: (2026)

Letter: Statins for Cirrhosis: Are We Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management?
von: Abdulrahman Ismaiel
Veröffentlicht: (2026)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’. Authors' Reply
von: Christian Labenz, et al.
Veröffentlicht: (2026)

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation
von: Thanawin Pramotedham, et al.
Veröffentlicht: (2026)

Letter: Statins for Cirrhosis: Are we Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management? Authors' Reply
von: Bernardo de Faria Moraes, et al.
Veröffentlicht: (2026)

Letter: Disease Stage and Absolute Risk in Evaluating the Branched‐Chain Amino Acid to Tyrosine Ratio in Cirrhosis. Authors' Reply
von: Takao Miwa, et al.
Veröffentlicht: (2026)

Letter: Refining Mortality Estimates in Severe Alcohol‐Associated Hepatitis—Addressing Heterogeneity and Prognostic Assessment
von: Shupeng Zhao, et al.
Veröffentlicht: (2025)

Letter: Using non‐invasive fibrosis tests and emerging diagnostics to enhance the accuracy of liver fibrosis staging in MASLD patients
von: Wenjun Meng, et al.
Veröffentlicht: (2024)

Letter: Attempted Validation of Villin‐1 as a Gut Barrier Marker in Decompensated Cirrhosis—Potential Confounding by Tubular Injury and Aetiology. Authors' Reply
von: David Tornai, et al.
Veröffentlicht: (2026)

Emerging Trends in Patients Hospitalised With Cirrhosis—Aetiologies, Complications and Outcomes Compared to Other Chronic Health Conditions
von: Julian Pohl, et al.
Veröffentlicht: (2025)

Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue?
von: Louise J. M. Alferink, et al.
Veröffentlicht: (2024)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing?
von: Qiang Hu, et al.
Veröffentlicht: (2024)

Letter: Social work and clinical synergy—Optimising health interventions for elderly DGBI populations
von: Rui Zhang, et al.
Veröffentlicht: (2024)

Barriers to Medical Care Are Frequently Reported by Patients With Cirrhosis
von: William Chai, et al.
Veröffentlicht: (2025)

Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue? Authors' Reply
von: Ting Wang, et al.
Veröffentlicht: (2024)

Persistence of Symptoms of Anxiety and Depression in Inflammatory Bowel Disease: A Longitudinal Follow‐Up Study
von: Christy Riggott, et al.
Veröffentlicht: (2025)

Letter: Refining the Understanding of Hepatic Steatosis and Cardiovascular Risk—Addressing Key Variables and Subgroup Analyses
von: Changhu Sun, et al.
Veröffentlicht: (2025)

Unstable Recompensation: An Intermediate Subtype in Patients With HBV ‐Related Decompensated Cirrhosis
von: Shuai Xia, et al.
Veröffentlicht: (2025)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing? Authors' Reply
von: Yewan Park, et al.
Veröffentlicht: (2024)

Editorial: Cumulative Impact of Clinical Disease Activity, Biochemical Activity and Psychological Health on the Natural History of Inflammatory Bowel Disease During 8 Years of Longitudinal Follow‐Up
von: Ben Massouridis, et al.
Veröffentlicht: (2025)

Systematic Review: Imaging‐Based Morphological Criteria for Liver Cirrhosis—A Call to Standardise
von: Mei Chin Lim, et al.
Veröffentlicht: (2026)

Letter: Resmetirom for treatment of MASH with children and adolescents
von: Yong‐Hai Zhou, et al.
Veröffentlicht: (2024)

Letter: Optimising public health policies to combat alcohol‐associated liver disease in youth—Addressing key methodological and regional challenges
von: Rui Zhang, et al.
Veröffentlicht: (2024)

Editorial: Statin Therapy in Cirrhosis: More Than Just Lipid‐Lowering
von: Emily Stephenson, et al.
Veröffentlicht: (2026)

Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
von: Yuki Utakata, et al.
Veröffentlicht: (2026)

Editorial: Linking Patients With Cirrhosis to Clinical Care—The Hurdles and Way Forward
von: Jimmy Che‐To Lai, et al.
Veröffentlicht: (2026)

Editorial: ABID‐LSM–A Promising Model for Predicting Decompensation Risk in MASLD Cirrhosis
von: Eduardo Vilar‐Gomez, et al.
Veröffentlicht: (2025)

Letter: The Simple Endoscopic Score for Predicting Crohn's Disease Progression—Not as Simple as It Sounds
von: Ziheng Calvin Xu, et al.
Veröffentlicht: (2025)

Letter: Boosting non‐invasive tests—Opportunities and challenges from resmetirom
von: Gong Feng, et al.
Veröffentlicht: (2024)

Letter: Tenofovir Alafenamide—The “Star of Potential” for Long‐Term Chronic Hepatitis B Treatment. A Deep‐Dive Analysis of Phase 3 Clinical Trials
von: YaoYao Dai, et al.
Veröffentlicht: (2025)

Editorial: Polypharmacy in MASLD—An Overlooked Epidemic Disproportionately Affecting Women and Patients With Cirrhosis
von: Mary Yue Wang, et al.
Veröffentlicht: (2025)

Editorial: Redefining Decompensation in Cirrhosis—More Than an Academic Playground? Authors' Reply
von: Lucie Simonis, et al.
Veröffentlicht: (2025)

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation. Authors' Reply
von: Mary Yue Wang, et al.
Veröffentlicht: (2026)

Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver Aetiology
von: Yu Shi, et al.
Veröffentlicht: (2025)